PHILADELPHIA — The Abramson Cancer Center (ACC) of the University of Pennsylvania will be presenting nearly 200 abstracts, of which 93 are oral presentations, during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition at the Georgia World Congress Center in Atlanta. Among research the team will present is the latest findings on the use of chimeric antigen receptor (CAR) immunotherapy, which researchers in the ACC pioneered, leading to the first FDA approval of the therapy in 2017. New studies being presented at ASH evaluated the efficacy of combination CAR T treatment, the impact of a patient's gut microbiota on CAR T response, and long-term remission associated with CAR T therapy.
SATURDAY, DECEMBER 11
Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects Clinically Relevant Abstract
Abstract #163, 12 p.m. - 1:30 p.m., B405-B407, Level 4, Building B (Georgia World Congress Center)
Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells
Abstract #166, 12 p.m. - 1:30 p.m., B405-B407, Level 4, Building B (Georgia World Congress Center)
The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
Abstract #253, 2 p.m. -3:30 p.m., Hall A1 (Georgia World Congress Center)
SUNDAY, DECEMBER 12
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
Abstract #469, 12 p.m. - 1:30 p.m., B401-B402, Level 4, Building B (Georgia World Congress Center)
